Unicycive Therapeutics Financials
| UNCY Stock | USD 0.68 0 0.29% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.39 | 0.7642 |
|
|
The essential information of the day-to-day investment outlook for Unicycive Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor Unicycive Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Unicycive Therapeutics.
Net Income |
|
Unicycive | Select Account or Indicator |
Understanding current and past Unicycive Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Unicycive Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Unicycive Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Unicycive Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Unicycive Therapeutics. Check Unicycive Therapeutics' Beneish M Score to see the likelihood of Unicycive Therapeutics' management manipulating its earnings.
Unicycive Therapeutics Stock Summary
Unicycive Therapeutics competes with Transcode Therapeutics, and Cardio Diagnostics. Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. The company was incorporated in 2016 and is based in Los Altos, California. Unicycive Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US90466Y1038 |
| CUSIP | 90466Y103 |
| Location | California; U.S.A |
| Business Address | 4300 El Camino |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | unicycive.com |
| Phone | 650 351 4495 |
| Currency | USD - US Dollar |
Unicycive Therapeutics Key Financial Ratios
| Return On Equity | -1.22 | ||||
| Price To Sales | 62.82 X | ||||
| Revenue | 675 K | ||||
| EBITDA | (30.18 M) | ||||
| Net Income | (30.54 M) |
Unicycive Therapeutics Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Retained Earnings | (3.7M) | (5.9M) | (15.9M) | (34.0M) | (64.5M) | (61.3M) | |
| Accounts Payable | 322K | 184K | 713K | 846K | 821K | 540.1K | |
| Total Current Assets | 19K | 204K | 18.4M | 2.6M | 13.4M | 14.1M |
Unicycive Therapeutics Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 139K | 244K | 628K | 6K | 82K | 77.9K | |
| Ebit | (2.0M) | (2.0M) | (9.0M) | (18.1M) | (30.5M) | (28.9M) |
Unicycive Therapeutics Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Unicycive Therapeutics. It measures of how well Unicycive is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Unicycive Therapeutics brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Unicycive had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Unicycive Therapeutics has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (10K) | (15K) | 16.6M | (16.1M) | 9.2M | 9.7M | |
| Net Income | (2.2M) | (2.3M) | (10.0M) | (18.1M) | (30.5M) | (29.0M) | |
| End Period Cash Flow | 15K | 147K | 16.6M | 455K | 9.7M | 4.9M |
Unicycive Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Unicycive Therapeutics's current stock value. Our valuation model uses many indicators to compare Unicycive Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Unicycive Therapeutics competition to find correlations between indicators driving Unicycive Therapeutics's intrinsic value. More Info.Unicycive Therapeutics is rated third in return on equity category among its peers. It is rated third in return on asset category among its peers . At this time, Unicycive Therapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Unicycive Therapeutics' earnings, one of the primary drivers of an investment's value.Unicycive Therapeutics Systematic Risk
Unicycive Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Unicycive Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Unicycive Therapeutics correlated with the market. If Beta is less than 0 Unicycive Therapeutics generally moves in the opposite direction as compared to the market. If Unicycive Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Unicycive Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Unicycive Therapeutics is generally in the same direction as the market. If Beta > 1 Unicycive Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Unicycive Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Unicycive Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Unicycive Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Unicycive Therapeutics November 28, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Unicycive Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Unicycive Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Unicycive Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Unicycive Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Unicycive Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 5.91 | |||
| Information Ratio | 0.1334 | |||
| Maximum Drawdown | 29.22 | |||
| Value At Risk | (7.41) | |||
| Potential Upside | 9.76 |
Additional Tools for Unicycive Stock Analysis
When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.